Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Hideo Takakusa"'
Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs
Publikováno v:
Pharmaceutics, Vol 16, Iss 1, p 47 (2023)
To meet unmet medical needs, middle-to-large molecules, including peptides and oligonucleotides, have emerged as new therapeutic modalities. Owing to their middle-to-large molecular sizes, middle-to-large molecules are not suitable for oral absorptio
Externí odkaz:
https://doaj.org/article/bb009938513c4b8398f878a8ffa137ed
Autor:
Kentaro Ito, Hideo Takakusa, Masayo Kakuta, Akira Kanda, Nana Takagi, Hiroyuki Nagase, Nobuaki Watanabe, Daigo Asano, Ryoya Goda, Takeshi Masuda, Akifumi Nakamura, Yoshiyuki Onishi, Toshio Onoda, Makoto Koizumi, Yasuhiro Takeshima, Masafumi Matsuo, Kiyosumi Takaishi
Publikováno v:
Current Issues in Molecular Biology, Vol 43, Iss 3, Pp 1267-1281 (2021)
Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease caused by out-of-frame or nonsense mutation in the dystrophin gene. It begins with a loss of ambulation between 9 and 14 years of age, followed by various other symptoms includ
Externí odkaz:
https://doaj.org/article/1b7c5f889f1a4ab4847f57aaebfdae57
Autor:
Hideo Takakusa, Norihiko Iwazaki, Makiya Nishikawa, Tokuyuki Yoshida, Satoshi Obika, Takao Inoue
Publikováno v:
Nucleic Acid Therapeutics. 33:83-94
Autor:
Daigo Asano, Koichi Nakamura, Yumi Nishiya, Hideyuki Shiozawa, Hideo Takakusa, Takahiro Shibayama, Shin-ichi Inoue, Tsuyoshi Shinozuka, Takakazu Hamada, Chizuko Yahara, Nobuaki Watanabe, Kouichi Yoshinari
Publikováno v:
Drug Metabolism and Disposition. 51:67-80
Autor:
Akifumi Nakamura, Akira Kanda, Kiyosumi Takaishi, Nobuaki Watanabe, Hideo Takakusa, Toshio Onoda, Masayo Kakuta, Yasuhiro Takeshima, Hiroyuki Nagase, Daigo Asano, Ito Kentaro, Takeshi Masuda, Yoshiyuki Onishi, Makoto Koizumi, Masafumi Matsuo, Nana Takagi, Ryoya Goda
Publikováno v:
Current Issues in Molecular Biology, Vol 43, Iss 90, Pp 1267-1281 (2021)
Current Issues in Molecular Biology
Volume 43
Issue 3
Pages 90-1281
Current Issues in Molecular Biology
Volume 43
Issue 3
Pages 90-1281
Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease caused by out-of-frame or nonsense mutation in the dystrophin gene. It begins with a loss of ambulation between 9 and 14 years of age, followed by various other symptoms includ
Autor:
Chie, Makino, Akiko, Watanabe, Manabu, Kato, Hideyuki, Shiozawa, Hideo, Takakusa, Daisuke, Nakai, Tomoyo, Honda, Nobuaki, Watanabe
Publikováno v:
Drug metabolism and pharmacokinetics. 45
Our previous study in rats demonstrated that the metabolic pathways of DS-8500a, a novel GPR119 agonist, include cleavage pathways: reductive cleavage of the oxadiazole ring in the liver and hydrolysis of the amide side chain. In the present study, i
Autor:
Chie Makino, Akiko Watanabe, Manabu Kato, Hideyuki Shiozawa, Hideo Takakusa, Daisuke Nakai, Tomoyo Honda, Nobuaki Watanabe
Publikováno v:
Drug Metabolism and Pharmacokinetics. 45:100459
Publikováno v:
Drug Metabolism and Disposition. 47:340-349
Esaxerenone (CS-3150) is a novel, nonsteroidal, selective mineralocorticoid receptor blocker. The absorption, metabolism, distribution, and excretion of esaxerenone were assessed in in vitro studies and in a clinical study, where [14C]esaxerenone (15
Autor:
Nobuyuki Murayama, Takashi Izumi, Shin-ichi Inoue, Takuo Washio, Makiko Yamada, Hideo Takakusa, Eiko Suzuki, Masakatsu Kotsuma, Makoto Takei
Publikováno v:
Xenobiotica. 47:1090-1103
1. Esaxerenone (CS-3150) is a novel non-steroidal mineralocorticoid receptor antagonist. The pharmacokinetics, tissue distribution, excretion, and metabolism of esaxerenone were evaluated in rats and monkeys. 2. Following intravenous dosing of esaxer
Autor:
Hiroyuki Kusuhara, Hideo Takakusa, Akiko Watanabe, Takako Kimura, Shin-ichi Inoue, Osamu Ando
Publikováno v:
Drug Metabolism and Disposition. 44:1608-1616
A series of fluoroquinolone compounds (compounds 1-9), which contain a common quinolone scaffold, inactivated the metabolic activity of CYP3A. The purpose of this study was to identify mechanism-based inhibition (MBI) among these fluoroquinolone comp